原文出处:BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe

原标题:全球首个软骨发育不全症药物!BioMarin公司C型利钠肽类似物vosoritide今年三季度申请上市!
本文来源自生物谷,更多资讯请下载生物谷APP(
http://www.bioon.com/m/)




























